Precision BioSciences (DTIL) Stock: Buy, Sell, or Hold?
DTIL - Precision BioSciences, Inc. Common Stock
$6.64
-0.14 (-2.06%)
âŧ
5d:
+15.08%
30d:
+4.9%
90d:
-8.41%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 02, 2026
8d
Get Alerted When DTIL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DTIL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DTIL is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DTIL is currently trading at $6.64, which is considered slightly high relative to its 30-day fair value range of $6.14 to $6.71.
Technical Outlook: Technically, DTIL is in a downtrend. Immediate support is located at $5.72, while resistance sits at $6.92.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.40 (+342.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DTIL is in a downtrend. Immediate support is located at $5.72, while resistance sits at $6.92.
Market Sentiment: The stock scores a mixed 47/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $29.40 (+342.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$6.14 -
$6.71
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (47/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 342.8% below Wall St target ($29.40)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.14 -
$6.71
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$1.07
(16.2%)
Support & Resistance Levels
Support Level
$5.72
Resistance Level
$6.93
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.57
Wall Street Target
$29.40
(+342.8%)
Revenue Growth (YoY)
37272.4%
Profit Margin
-117.0%
Share & Embed Analysis
Last updated: October 23, 2026 10:14 PM ET
Data refreshes hourly during market hours. Next update: 11:14 PM
Data refreshes hourly during market hours. Next update: 11:14 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DTIL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
PVLA
Palvella Therapeutics, IâĻ |
STRONG BUY
15 analysts |
$231 | 60 HOLD |
